Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.

This review discusses the interplay between epilepsy and reproductive endocrine disorders, examining the factors involved and emphasizing the importance of monitoring but reports no new research findings.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This article provides a framework for understanding hair disorders and treatment options in transgender individuals undergoing hormonal therapy and reports no new clinical results.

This review examines menopause's endocrinology, treatment history, and associated changes, noting key issues for midwife management but reports no new clinical results.

This article reviews the pathophysiology, diagnosis, and treatment of female pattern hair loss, highlighting the importance of early medical intervention to arrest hair loss progression, but reports no new clinical results.

This review examines the gender-specific challenges in preventing and treating venous thromboembolism in women and highlights the need for further research on safe and optimal treatment strategies.

This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This review outlines best practices for providing culturally competent care to transgender patients and discusses considerations for assessing disease risk, but reports no new research findings.

This review discusses the perimenopause, its symptoms, and management options, emphasizing the role of pharmacists in educating and advising women on treatment strategies and preventive health measures, but it reports no new results.

This review discusses the impact of gender affirming hormone therapy on cardiovascular outcomes in transgender individuals and reports no new clinical results; the authors underscore the need for more comprehensive studies.

This article discusses the clinical presentation and management challenges of menopausal acne, noting its multifactorial etiology and recommending tailored treatment approaches based on acne severity and associated features, without reporting new clinical results.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

The skin acts like an endocrine organ, making hormones that affect skin diseases and respond to stress.

This review discusses the use of hormonal therapies for managing acne vulgaris in adult women and reports no new clinical results, emphasizing the chronic and severe nature of acne in this population.

In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

Recent hair loss research shows some progress, especially in understanding male pattern baldness, but effective treatments for many types of hair loss are still lacking.

This case report describes the first instance of facial and oral mucosal hyperpigmentation and acanthosis nigricans linked to testosterone therapy in a patient with idiopathic hypogonadotropic hypogonadism.

This case report describes a rare instance of a patient with anorexia nervosa who was subsequently diagnosed with Cushing's syndrome, highlighting diagnostic challenges due to overlapping symptoms.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

This case study describes a severe instance of iatrogenic Cushing's syndrome induced by gamma-hydroxybutyric acid, exacerbated by combined use of betamethasone and anabolic steroids, in an HIV-positive patient on cobicistat-containing therapy.

This source emphasizes that menopause affects the onset and course of certain skin conditions, urging dermatologists to consider menopausal status and hormone therapy when treating skin diseases, while also calling for more diverse, dermatology-focused research to improve personalized care.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.